In contrast, results from the TROPION-PanTumor01 phase 1 trial demonstrated that in patients with advanced/metastatic hormone-positive/HER2-negative and triple-negative breast cancer, the incidence of any-grade pneumonitis was 5%, with grade 3 or higher pneumonitis occurring in 1.7% of patients [53]. Here, ERBB2 is linked to pneumonitis.